The EndoClot range promotes hemostasis and elevation in dissection or endoscopic resection of the submucosa during gastrointestinal procedures
HAMBURG, Germany, April 20, 2023 /PRNewswire/ -- Olympus today announced the launch of EndoClot® Adhesive (ECA), EndoClot® Polysaccharide Hemostatic Spray (PHS) and EndoClot® Submucosal Injection Solution (SIS) in the Europe region , Middle East and Africa (EMEA). This innovative wallet has been developed by EndoClot Plus, Inc. (EPI), which extended its distribution agreement with Olympus from the United States to EMEA in December 2022.
"We are delighted to expand our global collaboration with EndoClot Plus, Inc. Adding their solutions to our portfolio allows us to further our commitment to our customers as a provider of complete gastrointestinal solutions for advanced therapeutic procedures," explained Stefanie Kaufung, Unit Director EMEA GI Endotherapy Business at Olympus. "Endoscopic resection and management of associated bleeding are among Olympus' core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and thereby raise the standard of care" .
"EndoClot SIS helps me to have long-lasting mucosal lift with high elevation to create effective mucosal clearance and allow for precise ESD/EMR1, while EndoClot PHS and ECA may provide expanded options for treating emergent and residual bleeds or prevent rebleeding at resection sites," said Dr. David Tate, a physician at the University Hospital in Ghent, Belgium.
EndoClot ECA is a single-use medical device for sealing injuries, composed of hemostatic polymer (AHP). AHP is a durable hemostatic polymer due to its resistance to acids and bases in the gastrointestinal tract. Since it is a durable adhesive, it is recommended to use it only at the end of the intervention to stop and control exudative hemorrhage, prevent rebleeding and protect the wound from irritation caused by acids and bases.
EndoClot PHS and EndoClot SIS are based on EndoClot absorbable modified polymer (AMP®) technology. Starch-derived AMP technology has demonstrated an excellent safety profile.2 EndoClot's AMP particles work by absorbing water from the blood. The dehydration process causes a high concentration of platelets, red blood cells, and coagulation proteins, helping to accelerate the body's coagulation cascade.3 AMP particles are biocompatible, bioabsorbable, nonpyrogenic, derived from starch, and do not contain animal or human components.
Use in gastrointestinal procedures
Optimal elevation of the submucosa to facilitate dissection of polyps, adenomas, or early-stage cancers
EndoClot SIS (Submucosal Solution Injection), designed for use in gastrointestinal endoscopic procedures, promotes optimal submucosal elevation of polyps, adenomas, early-stage cancers, or other lesions of the gastrointestinal mucosa, prior to excision with an endoscopic scalpel or a handle. High, long-lasting elevation can create significant mucosal clearance that allows clinicians easier dissection. Thanks to the unique spiral design of the syringe, EndoClot SIS is precisely delivered to the desired area.
Reliable hemostasis during and at the end of the procedure
EndoClot ECA and EndoClot PHS allow healthcare professionals to apply an advanced powdered hemostat for hemostasis of non-variceal gastrointestinal bleeds (excluding Forrest 1a bleeding classification for EndoClot PHS) using controlled and constant air pressure via an air compressor. portable air.
EndoClot solutions are commercially available today in EMEA.
At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide the best solutions and services for early detection, diagnosis and minimally invasive treatment, with the goal of improving patient outcomes by raising the bar on care in specific disease states.
For more than 100 years, Olympus has pursued the goal of contributing to society by manufacturing products designed with the purpose of delivering optimal results to its customers around the world.
For more information, visit www.olympus-europa.com and follow us on LinkedIn: linkedin.com/company/olympusmedemea
1 ESD: endoscopic dissection of the submucosa / EMR: endoscopic resection of the mucosa2 Data on file with Olympus as of August 16, 20223 Bustamante-Balén M, Plumé G. Role of hemostatic powders in the endoscopic management of gastrointestinal bleeding. World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):284-92. doi: 10.4291/wjgp.v5.i3.284.
Photo - https://mma.prnewswire.com/media/2058335...Logo - https://mma.prnewswire.com/media/1774929...
View original content: https://www.prnewswire.com/news-releases/olympus-lanza-los-agentes-hemostaticos-endoclot-y-el-agente-de-inyeccion-submucosa-en-los-mercados-europeos-301803148.html